QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study
Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts
STAT3 targeting in dystrophic epidermolysis bullosa
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients
Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 “knock-out”
Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa
Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Features of Epidermolysis Bullosa Simplex due to KLHL24 Mutations in 3 Italian Cases
Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa
Epidermolysis bullosa simplex-generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype-phenotype correlation and in silico modeling analysis
Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy
Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network : Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease
Currently recruiting clinical therapy trials for Epidermolysis Bullosa (October 2020)
ERN-Skin clinical research update for Epidermolysis Bullosa (October 2020)